Industry Distribution:

• Biotechnology: approx. 70%
• Pharmaceutical Industry: approx. 20%
• Healthcare Services: approx. 10%

TOP 3 Markets:

• USA: approx. 55%
• Europe: approx. 25%
• Asia-Pacific: approx. 15%

The SPDR S&P Biotech ETF (XBI) mainly focuses on companies in the biotechnology sector, with a significant portion of revenues coming from the USA. Europe and the Asia-Pacific region are also significant markets, accounting for about 40% of revenues combined. Diversification across different regions and sectors within the healthcare industry provides investors with broad exposure to the biotechnology market.

SPDR Series Trust - State Street SPDR S&P Biotech ETF (ARCA:XBI) is an exchange-traded fund (ETF) and not a company that produces physical products.

This ETF invests in a variety of biotechnology companies included in the S&P Biotechnology Select Industry Index. Therefore, the ETF itself does not produce products but holds shares in companies operating in the biotechnology sector. The production sites of these companies vary depending on the individual company and are distributed worldwide.

Current Price: $92.50 (estimated for 2025 based on historical trends)

Growth Strategy:

The SPDR S&P Biotech ETF (XBI) pursues a strategy focused on diversification and innovation in the biotechnology sector. The ETF invests in a broad range of biotechnology companies to benefit from the latest scientific advancements and technological developments.

A key component of the strategy is the equal-weight allocation, ensuring that no individual companies dominate the portfolio. This reduces risk and enables the ETF to capitalize on a variety of growth opportunities.

Furthermore, the ETF focuses on companies engaged in research and development, particularly in areas such as genomics, personalized medicine, and novel therapeutic approaches. This emphasis on innovative technologies and groundbreaking research offers the potential for above-average growth.

Overall, the SPDR S&P Biotech ETF aims to benefit long-term from the dynamic developments in the biotechnology sector through a balanced and diversified investment strategy.

Commodities/Materials: No specific commodities or materials

The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund that invests in companies in the biotechnology industry. As an ETF investing in biotechnology company stocks, the fund itself does not import any commodities or materials.

However, the companies in which the ETF invests may import commodities or materials for their biotechnological developments and productions. These materials may include chemical substances, biological samples, or technical equipment sourced from various countries. The exact sources of imports depend on the individual companies within the ETF.

For detailed information on commodity imports, an analysis of the largest positions in the ETF and their annual reports would be necessary.

Competitive Advantage: Moderate to strong (estimated 2025)

The SPDR S&P Biotech ETF (ARCA:XBI) is an exchange-traded fund that invests in the biotechnology sector. Its competitive advantage lies in the diversification and broad coverage of the biotech market. The ETF provides investors with access to a variety of biotechnology companies, which reduces the risk of individual company failures.

Another advantage is the equal-weighted structure of the ETF, which prevents individual large companies from dominating the fund. This allows for a more balanced performance, especially in a volatile sector like biotechnology.

Since the biotechnology sector is characterized by innovations and regulatory changes, the ETF provides an opportunity to benefit from growth opportunities in this area while mitigating risk through diversification.

Institutional Investor Share: approximately 70% (estimated for 2025 based on historical trends)

Insider Buys/Sells: No significant insider transactions known (2025)

The SPDR S&P Biotech ETF (XBI) is a popular ETF among institutional investors as it offers broad diversification in the biotechnology sector. Historically, the share of institutional investors has been around 70%, which also represents a realistic estimate for 2025.

Insider transactions are less relevant for ETFs as they pertain to individual companies. For the XBI ETF, no significant insider buys or sells are known, as it consists of a basket of biotech stocks and is not directly influenced by company insiders.

Market share of SPDR S&P Biotech ETF (XBI): Estimated 20% (2025)

Top competitors and their market share:

1. iShares Nasdaq Biotechnology ETF (IBB): 25%
2. First Trust NYSE Arca Biotechnology Index Fund (FBT): 15%
3. VanEck Vectors Biotech ETF (BBH): 10%
4. Invesco Dynamic Biotechnology & Genome ETF (PBE): 8%
5. ARK Genomic Revolution ETF (ARKG): 7%

Moat Analysis:

The SPDR S&P Biotech ETF (XBI) holds a significant market share and is known for its broad diversification within the biotech sector. This provides investors with a balanced risk distribution, which can be seen as a certain moat. The ETF is equally weighted, meaning it is not dominated by the largest companies in the sector, thus offering broader exposure.

In comparison, the iShares Nasdaq Biotechnology ETF (IBB) has a higher market share and focuses more on larger, established biotech companies. This can be seen as an advantage, as these companies often have more stable earnings and less volatility.

The other competitors each offer different strategies and focuses, such as specialized approaches or a concentration on innovative technologies. XBI's moat lies in its diversification and equally weighted structure, while other ETFs may have an advantage through specific market segments or technologies.

Overall, XBI provides a solid moat through diversification, but some competitors may have a stronger moat in certain market segments due to specialized approaches and focus on established companies.

Industry Growth: 7.4% CAGR (2023-2028, forecast) Innovation Rate: High, with numerous new drug approvals in recent years Regulatory Support: Positive, with accelerated approval processes for biotech products

The SPDR S&P Biotech ETF (XBI) offers broad diversification in the biotechnology sector, known for its innovation and potential for above-average growth. The sector benefits from a strong pipeline of new products and a favorable regulatory environment that supports the development and market introduction of new therapies.

The biotechnology industry is expected to grow at an average annual growth rate of 7.4% by 2028, driven by increasing demand for innovative healthcare solutions. Additionally, technological advancements and investments in research and development are fostering the rate of innovation in this sector.

Investing in the XBI ETF provides access to a variety of companies that could benefit from these trends. This reduces the risk associated with investing in individual biotech stocks, which often depend on the development of individual products. Given the positive outlook for the industry and the diversification benefits, the XBI ETF could be an attractive investment opportunity.

Dividend yield: 0.00% (2023)

The SPDR S&P Biotech ETF (XBI) is known for not paying out regular dividends. The focus of this ETF is on capital appreciation through investments in biotechnology companies, which often reinvest profits to promote growth instead of paying dividends to shareholders.

The reliability of the payout is therefore not guaranteed, as the ETF does not make regular dividend payments. Investors who invest in XBI typically do so with the expectation of capital gains rather than dividend income.